Investigating a new treatment for spinal cord injuries using a drug called VersaMab-101
Toxicology and Efficacy Studies of Intrathecal VersaMab-101 for spinal cord injury treatment
This study is looking at a new drug called VersaMab-101 to see if it can help people with spinal cord injuries by promoting the healing of damaged nerves, which could improve movement and feeling.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versapeutics INC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-10697262 on NIH RePORTER |
What this research studies
This research focuses on developing and testing a new drug, VersaMab-101, for treating spinal cord injuries (SCI). The approach involves understanding how this drug can help regenerate damaged nerve connections in the spinal cord, which is crucial for restoring movement and sensation. The study will assess the safety and effectiveness of the drug in preclinical models, aiming to overcome barriers that prevent nerve regrowth after injury. By targeting the mechanisms that inhibit recovery, the research seeks to provide a potential therapeutic option for individuals suffering from SCI.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced spinal cord injuries, particularly those with incomplete injuries who may benefit from nerve regeneration.
Not a fit: Patients with complete spinal cord injuries or those who do not have the potential for nerve regeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that improves recovery and quality of life for patients with spinal cord injuries.
How similar studies have performed: While there have been various approaches to spinal cord injury treatment, this specific method using VersaMab-101 is novel and has not been extensively tested in clinical settings.
Where this research is happening
San Diego, United States
- Versapeutics INC — San Diego, United States (Active)
Researchers
- Principal investigator: Sun, Miao — Versapeutics INC
- Study coordinator: Sun, Miao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.